BioDelivery Sciences (BDSI) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioDelivery Sciences Provides Corporate Update and Reports First Quarter 2015 Financial Results
May 11, 2015 7:01 AM EDTRALEIGH, N.C., May 11, 2015 /PRNewswire/ --Â
BUNAVAIL® (buprenorphine and naloxone) buccal film showed a 25% average month-over-month growth in prescription sales over the quarter along with significant managed care wins
BELBUCA (buprenorphine HCl) buccal film for treatment of chronic pain PDUFA date of October 23, 2015 associated with $50 million milestone if approved
$10 million milestone payment received from Endo Pharmaceuticals in conjunction with NDA acceptance for BELBUCA
Clonidine Topical Gel Phase 3 data analysis complete; Pathway forward identified   Â
Buprenorphine Depot Injection for the maintenance treatment of opioid dependence and chronic pain on track for... More
